Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostat…
Prostate CancerMetastatic Castration-resistant Prostate CancermCRPC+3 more
Estimated
~$10 – $8,750
Blue Earth Therapeutics LtdNCT05413850
Phase 4
Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome
This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium label…
Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantMetastatic Prostate Cancer+8 more
Estimated
~$10 – $7,500
VA Greater Los Angeles Healthcare SystemNCT06706921